Newsbenzinga
Eli Lilly's Once-Daily Weight Loss Pill Orforglipron Shows Significant Reduction in Heart Disease Risk
· Published
Article summary
Eli Lilly says Phase 3 Foundayo (Orforglipron) data show reduced cardiovascular and type 2 diabetes risks in adults with obesity.
An excerpt from the original article.
Comments —
Loading comments…